Alnylam initiates Stage II study with ALN-TTRsc for treatment of ATTR Alnylam Pharmaceuticals.

Alnylam initiates Stage II study with ALN-TTRsc for treatment of ATTR Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today that it has initiated a pilot Phase II study with ALN-TTRsc announced, a subcutaneously shipped RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis http://levitraenligne.net/levitra-vs-cialis.html . The Phase II trial, which is currently open for enrollment, is aimed at analyzing the tolerability and preliminary scientific activity of ALN-TTRsc in TTR cardiac amyloidosis sufferers with familial amyloidotic cardiomyopathy – which is due to autosomal dominant mutations in the TTR gene, or senile systemic amyloidosis – which is due to idiopathic accumulation of wild-type TTR in the center.

ordre

American Stock Transfer & Trust Company, LLC shall become exchange agent for the Reverse Stock Split.. announced today that its Panel of Directors has collection a ratio of 1-for-8 because of its previously accepted reverse share split of its common share, and an anticipated effective day for the reverse share split of the later on of the filing with the Secretary of the Condition of Delaware of a certificate of amendment with respect to the reverse share split or August 9, 2013. The invert stock split was authorized by the Company's stockholders at its annual meeting of stockholders on, may 1, 2013, where the Organization's stockholders granted to the Board the authority to amend the Firm's certificate of incorporation to effectuate a reverse share split of its Common Stock at a ratio as high as and including 1-for-10, as dependant on the Board.